Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia (PRECAVER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00557778|
Recruitment Status : Completed
First Posted : November 14, 2007
Last Update Posted : April 28, 2011
|Condition or disease|
|Patients With Dyslipidemia|
|Study Type :||Observational|
|Actual Enrollment :||600 participants|
|Official Title:||Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia|
|Study Start Date :||November 2007|
|Actual Primary Completion Date :||September 2010|
|Actual Study Completion Date :||September 2010|
Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
- Assess the LDL-C reduction in the group exposed to the educational program compared to the group with routine orientation
- Assess cardiovascular risk through Framingham's score, · · Identify personal characteristics of the study population regarding their health, compile demographic characteristics regarding education, economic and cultural status.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00557778
|Campinas, Sao Paulo, Brazil|
|Study Director:||Jose Eduardo Neves, MD||AstraZeneca Brazil Ltda|
|Principal Investigator:||Francisco Jose Saraiva, MD||PUC-Campinas|